Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12348842 | 0.89 | OPRM1 (0.37) | L3MBTL1TP53BP1L3MBTL3DAOKCNH2 | |
| SCHEMBL13656367 | 0.88 | DAO (0.36) | DAOKCNH2CACNA1IKCNQ2OPRM1 | |
| SCHEMBL4446353 | 0.77 | — | — | |
| SCHEMBL16116527 | 0.74 | PIK3CD (0.55) | DAOKCNH2CACNA1IOPRM1SIGMAR1 | |
| SCHEMBL8445221 | 0.73 | ALDH1A1 (0.50) | L3MBTL1ALDH1A1THRBSIGMAR1 | |
| SCHEMBL12348825 | 0.73 | SMN1; SMN2 (0.41) | DAOALDH1A1THRBSIGMAR1 | |
| SCHEMBL15697002 | 0.73 | BRD4 (0.42) | DAOKCNH2CACNA1IOPRM1OPRL1 | |
| SCHEMBL9385097 | 0.72 | — | — | |
| SCHEMBL3431165 | 0.72 | — | — | |
| SCHEMBL17861677 | 0.72 | ALDH1A1 (0.51) | L3MBTL1TP53BP1L3MBTL3ALDH1A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1204652-B1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6649642-B2 | Useful in the treatment of autoimmune and other cathepsin related diseases. | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030087939-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | US | disclosed |
| EP-1204652-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-05-15 | — | — | EP | disclosed |
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | BEKKALI YOUNES (US) | 2001-11-15 | — | — | US | disclosed |
| US-6313117-B1 | TREATING AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001009110-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | SDHA, LONP1, SUCNR1 | L3MBTL1 2669/4885TP53BP1 887/4885L3MBTL3 4287/4885 |
| US-20030087939-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | SDHA, LONP1, SUCNR1 | L3MBTL1 2669/4885TP53BP1 887/4885L3MBTL3 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.